Pharmaceutical Operations Must Treat AI Prompts as Regulated Artifacts
Pharmaceutical companies are embedding generative AI into manufacturing, quality, and regulatory workflows without the governance controls these systems require. Regulators are already asking questions most organizations cannot answer, and the industry needs to establish prompting standards before enforcement actions force the issue.
A regulatory inspector reviewing a pharmaceutical submission or batch record now asks: What prompt was used? What model version generated this output? What parameters were set? Can you reproduce this result?
If your organization cannot answer these questions, the analysis has no regulatory standing. Not because generative AI is inherently untrustworthy, but because the process that produced the result was not controlled.
Prompts Are Now Regulatory Artifacts
When a prompt determines how GMP data is analyzed, how adverse events are summarized, or how a batch disposition decision is supported, that prompt functions as executable logic. It should be governed the same way organizations govern code in validated systems: with version control, change management, verification testing, and documentation.
The fact that a prompt is written in natural language rather than Python does not make it less consequential. If anything, natural language introduces more ambiguity, making governance more critical.
The FDA's January 2025 draft guidance on artificial intelligence in regulatory decision-making signals this direction. Credibility, transparency, and reproducibility are now central expectations. The pharmaceutical industry should not wait for warning letters or consent decrees to begin building this infrastructure.
Redefine Quality in Operational Terms
Quality has become a vague word in many organizations, synonymous with "good enough" or "it passed testing." In the context of generative AI proliferating across pharmaceutical operations, this vagueness is dangerous.
A working definition grounded in Crosby, Juran, and ISO 9000 is: Quality is conformance to fit-for-use requirements, demonstrated by objective evidence, scaled to risk, with data integrity treated as part of the requirement set.
Each element matters in pharmaceutical context:
- Conformance grounds quality in verifiable standards rather than subjective impressions.
- Fit-for-use ensures requirements are aligned with intended use, real-world conditions, and patient safety.
- Objective evidence makes the claim defensible under inspection.
- Scaled to risk prevents both over-documentation of trivial functions and under-control of critical ones.
- Data integrity as a requirement recognizes that in pharmaceutical systems, a record that cannot be trusted is a quality failure regardless of whether the software functions correctly.
Applied to generative AI tools in pharmaceutical operations, this definition sets a clear standard. Before the first prompt is written, there must be requirements. Those requirements must be fit for use in the intended GxP context. Outputs must be traceable back to those requirements. And the integrity of the data - including the prompt, model configuration, and context - must be controlled as rigorously as any other validated system element.
Without this, what organizations have is not quality. It is a prototype running in a GMP environment.
Five Concrete Starting Points
1. Establish prompting standards. Define how prompts must be authored, versioned, reviewed, and maintained when they generate or influence regulated content. At a minimum, address version control, model identity and configuration parameters, traceability between prompts and outputs, and clear criteria for when a prompt revision requires formal change control.
2. Require secondary human review for high-risk actions. Risk-based tiering should scale human oversight to the consequence of the AI-assisted action. For high-risk applications - those influencing patient safety, regulatory submissions, or GMP/GLP/GCP decision-making - mandatory secondary review is essential. The human is responsible for the decision, not the tool. AI output is decision support, not decision authority.
3. Extend AI governance policy to cover prompting and generative AI use. Define which generative AI tools are authorized for GxP contexts, who is permitted to use AI-generated outputs in regulated workflows, and what documentation is required before AI-assisted content enters a controlled record. Establish that the human is the author of record for any regulated content, regardless of how that content was drafted.
4. Make the prompting process and its output self-explanatory. When a regulatory inspector reviews a record generated or influenced by AI, the process should be self-explanatory. The prompt, model configuration, input data context, and resulting output should together tell a coherent, traceable story that a reviewer can follow without requiring narration from the original author.
5. Build credibility and transparency into both process and output. Credibility means showing the AI system is fit for intended use through validation, performance monitoring, and evidence that outputs are reliable in the specific context of use. Transparency means showing how the process works: what inputs drive outputs, what parameters and model versions are in play, and what human oversight is applied.
The Cost of Doing It Wrong
In pharmaceutical manufacturing, the price of nonconformance is measured in rejected batches, FDA 483 observations, warning letters, and delayed product launches. Building quality in from the start has always cost less than fixing what went wrong.
When leaders encourage teams to build tools through rapid generative AI coding - sometimes called "vibe coding" - without ensuring quality is built in from the first design decision, technical debt accumulates in days instead of months. In a regulated industry, technical debt is not merely an engineering inconvenience. It is a compliance liability with direct implications for product quality and patient safety.
The pharmaceutical organizations that establish these controls now, before regulators require them, will lead the next generation of innovation. The ones that do not will discover the lesson through failed submissions, compliance observations, and compromised data that could have been prevented.
Generative AI can write the code. It cannot generate accountability. That responsibility remains with your operations team.
Learn more about prompt engineering as a controlled discipline, or explore AI for Operations to understand how to build quality into AI-assisted workflows from the start.
Your membership also unlocks:
